Beigene

This study tested a new drug called gimistotug (BGB-A445) combined with other experimental drugs in 35 people with advanced non-small cell lung cancer who had already received standard treatments like immunotherapy and chemotherapy. The main goal was to see if the combination cou…

This study tested a drug called tislelizumab in 46 people whose Hodgkin lymphoma had come back or didn't respond to prior treatments. The goal was to see if the drug could shrink or eliminate tumors. Participants received the drug until their disease worsened or side effects beca…

This early-stage study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The study is no…

This study tested whether adding zanubrutinib to obinutuzumab works better than obinutuzumab alone for adults with follicular lymphoma that came back or didn't respond to prior treatments. About 217 participants were randomly assigned to one of the two groups. The main goal was t…

This study tested whether giving the immunotherapy drug tislelizumab together with chemotherapy or chemoradiotherapy before surgery could help people with a certain type of esophageal cancer. About 70 adults with resectable esophageal squamous cell carcinoma took part. The main g…

This study tested the drug tislelizumab given before surgery in 33 people with early-stage (stage II-III) colorectal cancer that has specific genetic changes (MSI-H or dMMR). The goal was to see if the drug could shrink or eliminate the tumor before surgical removal. The main mea…

This study tested whether adding a new drug (ociperlimab) to a standard immunotherapy (tislelizumab) and chemotherapy helps people with advanced non-small cell lung cancer that cannot be removed by surgery or has spread. About 272 adults who had not received prior treatment for t…

This study tested a drug called zanubrutinib in 65 adults with a hard-to-treat type of lymphoma (DLBCL) that has a specific gene change (CD79B mutation) and has come back or not responded to prior treatment. Participants took the drug as a pill and were monitored for tumor shrink…

This study tested giving the immunotherapy drug tislelizumab, alone or with other treatments, before surgery for stage II to IIIA non-small cell lung cancer. The goal was to see if these treatments could shrink tumors and improve outcomes. 121 adults participated, and the main me…

This study tested a new drug, tislelizumab, against the standard drug sorafenib as the first treatment for adults with advanced liver cancer that cannot be removed by surgery. 684 people from around the world took part. The goal was to see which drug works better and is safer. A …

This study tested a drug called zanubrutinib in 55 Japanese patients with certain types of blood cancers (B-cell malignancies) that had come back or stopped responding to prior treatment. The goal was to check the drug's safety, find the right dose, and see how well it shrinks tu…

This early-phase study tested a new antibody (BGB-A445) alone or with another drug (tislelizumab) in 204 people with advanced solid tumors, including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. While the treatment a…

This study tested whether adding the drug tislelizumab to standard chemoradiotherapy helps people with localized esophageal squamous cell carcinoma. 370 participants received either tislelizumab or a placebo alongside their cancer treatment. The main goal was to see if the drug c…

This study tested combinations of three immunotherapy drugs (surzebiclimab, alcestobart, and tislelizumab) in 147 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe doses and check for side effects, while also lo…

This study looked at a drug called zanubrutinib for people with certain types of B-cell lymphoma (like chronic lymphocytic leukemia or mantle cell lymphoma) who had to stop taking similar drugs (ibrutinib or acalabrutinib) because of bad side effects. The main goal was to see if …

This study tested a new combination of drugs (ociperlimab plus tislelizumab or rituximab) in 53 adults with diffuse large B-cell lymphoma that had come back or not responded to prior treatment. The main goals were to check safety and find the best dose. Researchers also looked at…

This study tested a new drug (BGB-10188) alone or with other drugs in 97 people with certain blood cancers or advanced solid tumors. The goal was to find the safest and most effective dose. However, the best dose could not be determined for all groups because not enough data was …

This study looked at how the body absorbs BGB-43395 when taken as two different tablet types and with or without food. Fifty-one healthy adults took a single dose of the drug. The goal was to gather information on drug levels and safety, not to treat any disease.

This study looked at how two common drugs—phenytoin and itraconazole—change the way the body processes BGB-16673. It involved 37 healthy adults aged 18 to 65. The goal was to measure drug levels in the blood, not to treat any disease.

This early-stage study tested the safety and how the body handles a new drug called BGB-23339 in 92 healthy adults. Participants received single or multiple doses of the drug, and researchers monitored for side effects and changes in vital signs and lab values. The goal was to ga…